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Abstract
Purpose Based on multiple large clinical trials conducted
over the last decades guidelines for implantable cardioverter-
defibrillator (ICD) implantations have been evolving. The
increase in primary prophylactic ICD implantations chal-
lenges us to be critical towards the indications in certain
patient populations.
Methods We retrospectively collected patient characteristics
and rates of appropriate and inappropriate ICD therapy,
appropriate and inappropriate ICD shock and mortality of
all patients who received an ICD in the University Medical
Center Utrecht (UMCU) over the years 2006–2011.
Results A total of 1075 patients were included in this anal-
ysis (74 % male, mean age 61±13 years, left ventricular
ejection fraction 30±13 %); 61 % had a primary indication
and 58 % had ischaemic heart disease. During a mean
follow-up period of 31±17 months, 227 of the patients
(21 %) received appropriate ICD therapy (149 (14 %) pa-
tients received an appropriate ICD shock). Females, patients
with a primary prophylactic indication and patients with non-
ischaemic heart disease experienced significantly less ICD
therapy. Only a few patients (54, 5 %) received inappropriate
ICD therapy; 33 (3 %) patients received an inappropriate
ICD shock. Fifty-five patients died within one year after ICD
implantation and were therefore, in retrospect, not eligible
for ICD implantation.
Conclusion Our study confirms the benefit of ICD implanta-
tion in clinical practice. Nevertheless, certain patients experi-
ence less benefit than others. A more patient-tailored risk
stratification based on electrophysiological parameters would
be lucrative to improve clinical benefit and cost-effectiveness.
Keywords Implantable cardioverter-defibrillator . Primary
prevention . Secondary prevention . Ventricular arrhythmia .
Mortality
Introduction
For almost 30 years, implantable cardioverter defibrillators
(ICD) have been used in the prevention of sudden cardiac
death caused by life-threatening cardiac arrhythmias. In
1984, the first ICD implantation in the Netherlands was
performed at the University Medical Center Utrecht
(UMCU). Over the last decades, multiple studies, including
series of randomised controlled trials, have demonstrated a
beneficial effect of an ICD in the prevention of sudden
cardiac death [1–8]. In particular, in patients with ischaemic
heart disease and impaired left ventricular function, primary
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prophylactic ICD implantation was proven to be effective
[3, 6, 8]. In patients with non-ischaemic cardiomyopathy,
however, trials had difficulties reaching statistical signifi-
cance, because of the low incidence of life-threatening tachy-
arrhythmias in these patients [6]. Guidelines have been
evolving over the years incorporating the evidence of recent
trials [9–11]. In the last decade the evidence about primary
prophylactic ICD therapy produced a steep increase in the
number of ICD implantations in Western Europe countries. A
shift in indication from predominantly secondary to primary
prophylaxis occurred due to a significantly higher number of
suitable candidates, which increased further with the broad-
ening of indications in the guidelines of 2008 [9]. However,
recent reports express concerns about cost-effectiveness and
the benefit-complication ratio [12–15]. The question is in
which patients and in how many of them we actually prevent
a sudden cardiac death. Critical articles about the sense and
non-sense of ICD implantation for primary prophylaxis in
certain patient populations have given rise to some doubts
making it more difficult to implement and interpret guidelines
accurately [16, 17]. This results in a higher number of non-
evidence-based ICD implantations on one hand and a sub-
stantial number of patients eligible for ICD implantation,
which are not recognised on the other.
We retrospectively collected several patient characteris-
tics for all patients who received an ICD implant in the
University Medical Center Utrecht (UMCU) over the years
2006–2011. In this study we give an overview of ICD
implantations in this centre and present rates of, and risk
factors for, appropriate and inappropriate ICD therapy, ap-
propriate and inappropriate ICD shock and mortality. Sub-
sequently, we evaluate the adherence to international
guidelines in clinical practice and provide directions for
future indications for ICD implantation.
Materials and methods
Patient population and parameters
In our tertiary centre, we retrospectively identified all new
ICD implantations from 2006 until the end of 2011. In the
determination of different indications, the class I or II rec-
ommendations of the 2006 and 2008 ACC/AHA/HRS
guidelines were used [9, 18]. Obtained variables included
patient demographics, indication for implantation, New
York Heart Association (NYHA) functional class, left ven-
tricular ejection fraction (LVEF), renal clearance, history of
diabetes, documented rhythm disorders, QRS duration,
medication and device settings.
The LVEF was rated by transthoracic echography, nuclear
myocardial perfusion scan, or magnetic resonance imaging
(MRI). If more than one modality was available, preference
was given to LVEF provided by MRI. To determine renal
function at baseline, serum creatinine was used to calculate the
glomerular filtration rate (GFR) using theModification of Diet
in Renal Disease (MDRD) formula [19]. History of diabetes
and use of medication was also rated at baseline or at least as
close as possible to the date of implantation, with a maximum
of one month. To allocate the different antiarrhythmic drugs
into classes, the Vaughan Williams classification was used
[20]. Finally, specific information regarding device program-
ming was retrieved from the last visit to the outpatient clinic.
Data were collected from electronic medical records and
implantation reports by the first two authors. Collection of
follow-up data for all patients was completed by the end of
May 2012.
Implant technique and ICD programming
All devices were implanted by one of our cardiologists in the
Cardiac Catheterisation Laboratory of the UMCU. No thora-
cotomies were performed for implantation and all patients
received endocardial leads and subpectoral or subcutaneous
device placement. Devices from Boston Scientific (Natick,
MA, USA), Medtronic (Minneapolis, MN, USA) and St. Jude
Medical (St Paul, MN, USA) were used. Programming of
ventricular tachycardia (VT)/ventricular fibrillation (VF)
zones, monitor zones and additional programming of
antitachycardia pacing (ATP) therapy was decided by patient’s
cardiologist.
Definitions
Ischaemic cardiomyopathy as underlying heart condition was
defined as either the presence of coronary artery disease, myo-
cardial infarction or both. A history of atrial tachyarrhythmia
was documented when patients suffered from atrial fibrillation
or atrial flutter, or had experienced episodes of these arrhyth-
mias in the past. We defined ICD therapy as delivery of either
antitachycardia pacing (ATP) and/or ICD shock (cardioversion
or defibrillation), which was considered appropriate when
given in the presence of a ventricular tachyarrhythmia. Therapy
given in the absence of a ventricular tachyarrhythmia, but
triggered as a result of i.e. supraventricular tachycardia or due
to technical disturbances, was defined as inappropriate ICD
therapy. For the incidences of either inappropriate or appropri-
ate ICD shock all patients who received an ICD shock were
counted regardless of delivery of previous ATP. For incidences
of both ICD therapy and ICD shock, each patient is counted
once, regardless of the number of events in one patient.
Statistical analysis
Categorical variables were presented as absolute numbers
and percentages and continuous variables were expressed as
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a mean with an upper and lower standard deviation. To
compare differences between baseline characteristics, the
independent sample t-test was used for continuous variables
and the chi-square test for categorical variables.
Multivariate Cox regression analysis was used to deter-
mine independent risk factors for appropriate and inappro-
priate ICD therapy, appropriate and inappropriate ICD
shock and mortality. Kaplan-Meier curves were constructed
to determine cumulative incidence of appropriate ICD
shocks. To perform these analyses, SPSS 20.0 (IBM,
USA) was used.
Results
From January 2006 to December 2011, 1075 de novo ICD
implantations were performed at the UMCU.
Baseline characteristics
An overview of the baseline characteristics of the 1075
patients is presented in Table 1. In 2006, 134 ICD im-
plantations were performed; in 2011 this amount had
almost doubled (229, +171 %). ICDs were implanted for
primary prevention in 654 patients (61 %); 626 (58 %)
patients had ischaemic heart disease. There was a 3/1
male versus female ratio. Of all de novo implants almost
30 % consisted of cardiac resynchronisation therapy –
defibrillator (CRT-D) implantations. The mean age of the
total population was 61±13 years, the mean LVEF 30±
13 %, and 78 % used at least one antiarrhythmic agent,
particularly beta-blockers (71 %). A history of atrial ar-
rhythmia was seen in 28 % of the patients. During a mean
follow-up period of 31 months (± 17 months), 155 pa-
tients died.
Ischaemic versus non-ischaemic cardiomyopathy
In Table 1, a distinction was made between patients with
ischaemic cardiomyopathy (ICM) and non-ischaemic car-
diomyopathy (NICM). The mean age at implant in the
patients with NICM was lower (55±15 versus 66±10, p<
0.001) and the distribution between men and women was
more equal (male/female ratio of 5.3/1 versus 1.5/1). In
patients with ischaemic aetiology, the mean LVEF and the
GFR were significantly lower and diabetes mellitus type II
more prevalent.
Primary versus secondary indication for ICD implantation
The increase in the number of ICD implantations was mainly
based on the increase in primary prophylactic implants. The
percentage of patients with ICMwas significantly lower in the
patients with an ICD implanted for primary prevention com-
pared with secondary prevention (54 % and 64 %, respective-
ly, p<0.001). LVEF was significantly higher in patients
implanted for secondary prevention than in patients with a
primary indication, 36±15 % versus 27±11 %, respectively
(p<0.001).
ICD settings
A single zone (VF only) was installed in 7 % of the
patients, two zones (VT+VF) in 80 % and three zones
(VT-1, VT-2 and VF) in 10 %. In the VT-1, VT-2 and
VF zone the mean rates installed were 180±13, 188±12,
and 226±17 beats/min, respectively. In the remaining 3 %,
data of the ICD settings were not available. In approxi-
mately 90 % ATP was programmed (either as single ther-
apy or prior to shock therapy). VT/supraventricular
tachycardia (SVT) discrimination algorithms were
programmed in the VT zones in all patients. No major
differences between monitor and therapy zones were ob-
served between the different subpopulations of patients that
experienced ICD therapy.
ICD therapy
In the total population of 1075 patients, 227 patients (21 %)
received at least one episode of appropriate ICD therapy
(149 appropriate ICD shocks (14 %)) during the mean
follow-up period of 31±17 months. Inappropriate ICD ther-
apy was seen in 54 patients (5 %), 33 patients (3 %) received
an inappropriate ICD shock.
Cumulative incidence of appropriate ICD shock was
7 % at one year, 16 % at three years and 23 % at five
years. When corrected for several baseline characteristics
by multivariate Cox regression analysis, a secondary in-
dication, ICM, decreased LVEF (≤25 %) and the male
gender were independent predictors for appropriate ICD
shock, with hazard ratios (HR) of 1.8 (95 % CI: 1.3–2.5;
p=0.001), 1.6 (95 % CI: 1.1–2.3; p=0.023), 1.6 (95 % CI:
1.2–2.3, p=0.004) and 2.3 (95 % CI: 1.4–3.8; p=0.001),
respectively (Fig. 1). Gender showed to be the most
important risk factor for appropriate ICD shocks, with
men having a more than doubled risk for appropriate
ICD shock. When we only analysed patients who had an
ICD implanted for primary prophylaxis, the incidences of
appropriate ICD therapy and appropriate ICD shock were
17 % (109 patients) and 10 % (68 patients), respectively.
Ischaemic aetiology and decreased LVEF (<25 %)
remained independent risk factors for appropriate ICD
shock.
A history of atrial tachyarrhythmia was a predictor
for inappropriate ICD shock (HR 4.8, 95 % CI: 2.4–9.7,
p<0.001).
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Mortality
Of the 155 patients who died, 50 patients (5 %) died within
the first year after implantation. Over the follow-up period
of 31±17 months, 104 patients (10 %) died without receiv-
ing prior appropriate ICD therapy.
The yearly mortality rate was 5.6 %. The most important
risk factors for mortality were: decreased GFR (≤60) (HR 2.3,
95 % CI: 1.6–3.2; p<0.001), a decreased LVEF (≤25 %) (HR
2.1, 95 % CI:1.5–3.0; p<0.001) and the male gender (HR 1.9,
95 % CI: 1.3–3.0; p=0.004). In patients with a primary
indication, a prolonged QRS duration (>130 ms) was an
additional risk factor for mortality. In patients with ICM,
diabetes mellitus type II, older age (>70 years) and decreased
LVEF (<25 %) were predictive of mortality, while the use of
beta-blockers decreased the risk of mortality. In the non-
ischaemic population, decreased GFR (<60) and decreased
LVEF (<25 %) were the most important risk factors. At
baseline, decreased GFR (<60), non-ischaemic aetiology and
a history of AF were predictive of mortality within one year
after primary prophylactic ICD implantation.
Discussion
Interpretation of and adherence to guidelines
Baseline characteristics
The demographics of our patient population are comparable
with the characteristics of patients enrolled in the large
randomised controlled trials [3, 6, 8]. Since the indication
for ICD therapy is determined on the basis of these large
trials, this seems a logical consequence, but it is worth
mentioning that patients participating in randomised con-
trolled trials may not be representative of patients typically
seen in clinical practice. Only the incidence of a history
of atrial tachyarrhythmias was substantially higher in our











Number (%) Number (%) Number (%) Number (%) Number (%)
Implantations
2006/2007/2008/ 134/144/148/ 80/97/93/ 54/47/55/ 57/67/67/ 77/77/81/
2009/2010/2011 213/207/229 112/113/131 101/94/98 86/60/71 127/147/158
1/2/3 leads 596/165/314 379/97/150 217/68/164 281/82/58 315/83/256
Ischaemic/non-ischaemic aetiology 626(58)/449(42) - - 271(64)/150(36) 355(54)/299(46)*
Primary/secondary indication 654(61)/421(39) 355(57)/271(43) 299(47)/150(33)* - -
Demographics
Age(years, mean, SD) 61±13 66±10 55±15* 62±14 61±13
Sex (male/female) 796(74)/279(26) 526(84)/100(16) 270(60)/179(40)* 337(80)/84(20) 459(70)/195(30)*
Clinical parameters
LVEF (%; mean, SD) 30±13 28±10 33±17* 36±15 27±11*
NYHA class (I/II/III/IV) 75/194/267/14 43/141/140/4 32/53/127/10 29/45/39/4 46/149/228/10
QRS duration (ms, mean, SD) 127±33 125±29 130±37* 120±30 132±34*
Diabetes mellitus II 204(19) 156(25) 48(11)* 66(16) 138(21)*
GFR (mean, SD) 67±22 65±20 72±23* 71±22 65±21
History of atrial tachyarrhythmia 300(28) 174(28) 126(28) 125(30) 175(27)
Loss to follow-up 116(11) 67 49 63 53*
Medication at baseline
Antiarrhythmic agent 842(78) 520 322* 317 525*
Class II a 705(66) 436 269* 452 253
Class III a 102(9) 88 53 59 82
Mean follow-up period 31±17 months
SD standard deviation, LVEF left ventricular ejection fraction, NYHA New York Heart Association, OHCA out-of-hospital cardiac arrest, GFR
glomerular filtration rate (MDRD)
*p<0.05
a Alone or in combination with another antiarrhythmic drug
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population since this was an exclusion criteria in most of
these trials.
When we divide our population on the basis of aetiology,
we observed that patients with ICM were older, predomi-
nantly male and had more comorbidities. The differences
seen between LVEF in the ischaemic and non-ischaemic
group can be explained by the fact that in a substantial
number of the patients with NICM the indication for ICD
implantation was not solely based on LVEF. A large pro-
portion of patients with NICM have an underlying heart
disease other than dilated cardiomyopathy, for whom risk
factors such as unexplained syncope or hereditary taint (e.g.
ARVC, LQTS) are more decisive when considering ICD
implantation. Furthermore, NICM is more frequent in youn-
ger individuals and is associated somewhat more often with
the female gender [21]. In our study we observed a more or
less equal distribution between the two genders and a lower
age at implant in the non-ischaemic population. The patients
with a hereditary heart disease, such as ARVC, often receive
an ICD early in life, which can attribute to the latter.
Increase in the number of implantations
As expected we observed an increase (171 %) in the number
of implantations over the years 2006–2011. As mentioned
before, this increase in (primary indications for) implanta-
tions can be explained by the implementation of large
randomised controlled trials following the latest guidelines
of 2008, which led to a broadening of indications [9].
Although we see a steady increase in implantations, we
would have expected an even larger increase. On one
hand, we could explain the limited increase by lack of
adherence to the guidelines in clinical practice, but it can
also represent a critical view on evidence and interpreta-
tion of these concomitant guidelines. Therefore, knowl-
edge of current guidelines is crucial, not only to identify
those eligible for ICD implantation but also those exempt
from an indication [22, 23].
In the following paragraphs we will reflect on the in-
cidences of inappropriate and appropriate ICD therapy and
inappropriate and appropriate ICD shock and mortality. We
should be careful about interpreting the absolute numbers
since certain variables are time dependent. For example, a
larger proportion of patients who received an ICD for pri-
mary prophylactic reasons received the ICD in the last
couple of years of this study; therefore the follow-up of
these patients will be relatively shorter than for the patients
who received an ICD for secondary prophylaxis. With the
multivariate Cox regression analysis, we corrected for this
by taking the time to the (first) event into account.
Fig. 1 Cumulative hazard for appropriate shock over time divided by different subpopulations
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Appropriate ICD therapy
In the current study, 227 (21 %) patients of our total popu-
lation received appropriate ICD therapy after a mean follow-
up of 31±17 months, which corresponds to an annual ap-
propriate ICD therapy rate of 8.1 %. This number compares
well with other registries [24, 25]. We found an appropriate
ICD shock rate of 14 %. A secondary indication, ischaemic
aetiology, a decreased LVEF and a male gender were iden-
tified as independent risk factors for appropriate ICD shock.
The annual appropriate ICD shock rate of 5.4 % compares
well with the findings of an earlier study by Van Welsenes et
al., performed in Leiden, the Netherlands, over the years
1996–2008 [24]. In their population of 2134 patients with
both primary and secondary indication, they found an an-
nual appropriate ICD shock rate of 5.9 %. The appropriate
ICD shock rate in our primary prophylactic population was
lower with an annual appropriate ICD shock rate of 4 %. In
the SCD-HeFT trial (patients with a primary indication and
both ischaemic and non-ischaemic heart disease) an annual
appropriate ICD shock rate of 5.1 % was seen. Follow-up
data from the DEFINITE trial (patients with a primary
indication and non-ischaemic heart disease) showed an in-
cidence of 7 % of appropriate ICD shock after 29 months of
follow-up (annual appropriate ICD shock rate 2.9 %). The
incidence of appropriate ICD shock in our patients
implanted for primary prophylaxis and non-ischaemic heart
disease was 4 % (annual appropriate ICD shock rate of
1.7 %). The somewhat higher ‘appropriate’ ICD shock rates
in both the SCD-HeFT trial as well as the DEFINITE trial
could be explained by the ICD settings. In both trials ICDs
were programmed with shock therapy only (no ATP) at a
single zone of >187 beats/min and >180 beats/min, respec-
tively. After three years of follow-up of the MADIT II study,
which consisted of patients with a primary indication and
ischaemic heart disease, 20 % of their patients experienced
an appropriate ICD shock at least once [26]. In our primary
prophylactic patients with ischaemic heart disease this rate
was found to be 16 % after approximately 2.5 years, which
might be explained by the shorter follow-up period and by
the unselected nature of our patient population in contrast to
the large prospective trials such as MADIT II.
When we only select the patients who received an ICD
for primary prophylaxis, a lower incidence of appropriate
ICD therapy and ICD shocks was seen in the subpopulation
with NICM compared with the ischaemic group. The DEF-
INITE and SCD-HeFT failed to reach statistical significance
for the benefit of ICD implantation for primary prophylaxis
in the subset of patients with NICM. Nevertheless, a trend
toward reduced mortality was seen [3, 6]. It should be noted
that the DEFINITE trial demonstrated significant effective-
ness of ICD therapy in NICM patients for preventing death
from cardiac causes, but not all-cause death. The lack of
statistical significance is probably due to low mortality in
the NICM population that was also the reason for prema-
turely stopping the AMIOVIRT and CAT trial [27, 28].
Furthermore, a sub-analysis of the SCD-HeFT trial showed
a relatively high mortality due to pump failure instead of
arrhythmic death in patients with non-ischaemic cardiomy-
opathy and NYHA functional class III. This implies a rela-
tively small absolute mortality benefit, and therefore a
higher number needed to treat (25 versus 18 ICD implanta-
tions to prevent one death in two years for NICM patients
and ICM patients respectively) [29]. Furthermore, if these
patients receive appropriate ICD therapy, the question is:
‘how many life years can be gained due to appropriate ICD
therapy?’ In patients with end-stage heart failure recurrent
VTs can be a sign of progression of the impaired LV func-
tion. Although the ICD can successfully treat ventricular
tachyarrhythmias, it cannot prevent death from pump fail-
ure. It is also important to realise that ICD shock, and
certainly ICD therapy, cannot be replaced 1:1 by a prevented
sudden cardiac death. Multiple trials have shown that the
incidence of ICD shocks is substantially higher than the
incidence of sudden cardiac death.
As described in our results the male gender was one of the
independent risk factors for appropriate ICD therapy and
ICD shock in our population. When we divide the population
based on aetiology or indication, patients with ischaemic
heart disease and patients with an ICD implanted for second-
ary reasons received the most appropriate ICD shocks. The
male gender was more common in those subpopulations.
However, when we corrected for these variables, males still
had a higher probability to receive an appropriate ICD shock
(HR 2.3, 95 % CI: 1.4–3.8; p=0.001). The registry of Wilson
et al. and the follow-up study of MADIT II also found a
higher number of men in their appropriate ICD shock popu-
lation [26, 30]. Moreover, the long-term follow-up study of
the MADIT II cohort showed a smaller benefit of ICD
implantation in women [31]. Differences in repolarisation
and in arrhythmogenic substrate are suggested to cause this
difference in benefit of ICD implantation [32–34]. Risk
factors for appropriate ICD therapy could therefore be differ-
ent in the female population. Since some studies also reported
a higher complication rate in females, it could be of impor-
tance to further elucidate whether this should have conse-
quences for patient selection and risk stratification [35].
When we exclude patients who received an ICD for sec-
ondary prophylaxis from the analysis, aetiology and decreased
LVEF remained independent risk factors for appropriate ICD
shock. Only gender was no longer an independent risk factor
though the incidence of appropriate ICD shock in females was
significantly lower than in males in patients with an ICD
implanted for primary prophylaxis. The low number of fe-
males and subsequent low number of events in this subpopu-
lation probably caused the analysis to be statistically
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underpowered. This supposition was supported by the fact
that when we analysed the risk factors for appropriate ICD
therapy (higher number of events), gender was an independent
risk factor for appropriate ICD therapy.
Inappropriate ICD therapy
Inappropriate ICD therapy, and inappropriate ICD shock in
particular, leads to an impaired quality of life and psycho-
logical and psychiatric effects [36, 37]. As a matter of
course inappropriate ICD therapy must be prevented to the
extent possible. In our population we found an inappropriate
ICD shock rate of 3 % after 31±17 months of follow-up.
This number is much lower compared with other registries
or the landmark trials. In the study by Van Welsenes et al.,
14 % of their patients experienced an inappropriate ICD
shock [24, 38]. The follow-up studies of SCD-HeFT, DEF-
INITE and MADIT II found inappropriate ICD shock rates
of 10 %, 10 % and 11.5 % after 45, 29 and 20 months of
follow-up, respectively [3, 39, 40]. In the MADIT II study
and the registry of Van Welsenes et al. prior atrial fibrillation
was predictive of inappropriate ICD shock [24, 38, 40]. Our
study confirms prior atrial tachyarrhythmia to be a risk
factor for inappropriate ICD shock (HR 4.8, 95 % CI: 2.4–
9.7, p<0.001) and also patients with NICM received a
higher number of inappropriate ICD shocks (HR 2.1, 95 %
CI:1.0–4.1, p<0.038). In other studies a higher incidence of
inappropriate ICD shocks was seen in younger patients and
patients with renal dysfunction [40, 41]. Regarding the low
incidence of inappropriate ICD shock in our population, it is
important to emphasise that the number of inappropriate
ICD shocks is greatly dependent on device settings. At the
UMCU our philosophy is to program the device only for the
treatment of fast VT or VF (life-threatening tachyarrhyth-
mias); slow VTs (haemodynamically stable VTs) were treat-
ed by VT ablation or pharmacologically. Furthermore,
SVT/VT discriminators are enabled in the VT zones of all
patients. The more than double inappropriate ICD shock rate
in the SCD-HeFT trial, for example, can be related to the
fact that all ICDs were programmed with shock therapy at a
single zone of >187 beats/min without discrimination be-
tween VT and SVT [3].
Risk factors for mortality
One prerequisite of ICD implantation is a life expectancy of
more than 1 year. Furthermore an ICD will only be feasible
if appropriate ICD therapy is delivered before the patient
dies. Estimating risk at death is therefore useful and often
already an important consideration in clinical practice. In
our population, 50 patients died in the first year after im-
plantation, and therefore, in retrospect, were not eligible for
ICD treatment. Furthermore, 10 % of the patients died
without receiving appropriate ICD therapy. Different factors
were associated with death in the different subpopulations.
The risk factors we found were comparable with other
registries [42, 43]. In our study impaired renal function
was the most important risk factor for mortality.
Study limitations
In this analysis there was no control population available.
Hence, we could not compare the adherence to guidelines in
patients with and without ICD implantation. Furthermore,
we performed a retrospective study, which entails some
disadvantages. All the analysed data were retrieved from
electronic medical records. Some information was not
recorded in the medical records of all patients, such as
NYHA class and LVEF. We noticed that in the 58 cases in
which the quantification of LVEF in percentages was lack-
ing, the LVEF was predominantly described as normal or
good. This could probably cause bias. To calculate the aver-
age LVEF we used 1017 cases in which LVEF was quantified
as a percentage. For the multivariate Cox regression analysis,
in which we used LVEF <25% as a variable, we used 41more
cases (1058). In these 41 cases we could be certain, based on
the echocardiogram quantification and medical records, that
these patients had to have an LVEF >25 %. In this way the
probable bias that can occur based on the abovementioned is
avoided.
We collected recent data, which led to a relatively short
follow-up period. The loss of follow-up was mainly caused by
the fact that some patients, mostly elderly, return to their own
cardiologist in the referral hospital for routine check-up.
ICD implantation: where do we go from here?
Decreased LVEF has shown to have an inverse relationship
with cardiac mortality and approximately 50 % of the cardiac
deaths are a result of sudden death. Since no other reliable
methods are available for identifying in advance those patients
who are more likely to die from sudden death, LVEF is
considered a valuable criterion for ICD implantation [1, 3, 44].
Due to trial designs, left ventricular dysfunction has
developed into a key determinant for the selection of candi-
dates for prophylactic ICD implantation, even though a
causal relation between LVEF and the pathophysiology of
ventricular arrhythmias is not clearly demonstrated. Further-
more, prior research has shown that the largest proportion of
non-survivors of out-of-hospital cardiac arrest had an LVEF
of 30% or higher prior to the event, and would not have
been eligible for prophylactic ICD implantation [45, 46].
The relative risk for ventricular tachyarrhythmias in people
with a normal LVEF is much lower and the number to treat
very high. In our population the mean LVEF of patients with
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a secondary indication was 36±15%, comparable with the
three large secondary prevention trials which presented a
mean LVEF after out-of-hospital cardiac arrest of 32%–45%
[2, 5, 7]. Note that the patients with an ICD implanted for
secondary prophylaxis had a significantly higher number of
appropriate ICD shocks. On the other hand, impaired LVEF
(<25%) was an independent risk factor for appropriate ICD
therapy and ICD shock in the overall population and also in
the subgroup of patients implanted for primary prophylaxis.
As we can see in our population, patients with NICM,
patients with an ICD for primary prophylactic reasons, and
women experienced the lowest number of appropriate ICD
shocks, and therefore have the least benefit from ICD im-
plantation. At the moment, ICD implantation in these
groups is mainly based on the LVEF. Improvement of se-
lection of eligible patients by electrophysiological parame-
ters has been studied, but these studies often did not find a
hazard ratio greater than two. Furthermore, electrophysio-
logical tests are not feasible in all candidates for prophylac-
tic ICD implantation [47, 48]. The Alternans Before Cardiac
Defibrillator trial (ABCD trial [49]) was the first to suggest
to combine different electrophysiological parameters to in-
crease the predictive power to guide ICD therapy. The large
prospective European multicentre study, EUTrigTreat, em-
braces this idea. The study enrols patients with standard
indications for ICD implantation in a population consisting
of both ischaemic and non-ischaemic heart disease. It is an
observational trial with the aim to accurately stratify ICD
patients, who are at risk for ICD shock and mortality using
traditional risk markers as well as genetic markers. It com-
pares the predictive power and temporal changes of various
invasive and non-invasive electrophysiological tests such as
programmed ventricular stimulation (PVS), T-wave alternans
(TWA), beat-to-beat variability of repolarisation quantified as
short-term variability (STV), heart rate variability (HRV) and
heart rate turbulence (HRT) to determine which patients will
be at risk for life-threatening arrhythmias and will benefit from
ICD implantation [50, 51].
Conclusion
As in all Western European countries we experienced an
increase in the number of ICD implantations mainly based
on the increase in primary prophylactic implantations. The
rate of appropriate ICD shocks in our unselected population
corresponds to the large clinical trials, which confirms the
benefit of ICD implantation when following current guide-
lines. Nonetheless a significantly lower rate of appropriate
ICD shocks were observed in patients implanted for primary
prevention, patients with non-ischaemic cardiomyopathy
and women. This implies a lower ICD benefit or at least a
higher number needed to treat in these subpopulations. It
would be lucrative to improve the risk stratification and
patient selection for ICD implantation to accomplish opti-
mal clinical benefit and cost-effectiveness. The prospective
European multicentre study, EUTrigTreat, might contribute
to this by a more patient-tailored risk stratification based on
electrophysiological parameters. In our population few pa-
tients (only 3%) received an inappropriate ICD shock; we
attribute this to adequate ICD programming and alternative
treatment of slow VTs.
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